Azanidazole

Azanidazole is a nitroimidazole antiprotozoal agent that is under investigation for the treatment of Chagas disease. It is being developed by the Drugs for Neglected Diseases initiative (DNDi) and has reached Phase II clinical trials.

Mechanism of action[edit | edit source]

Azanidazole works by inhibiting the synthesis of DNA in the parasite that causes Chagas disease, Trypanosoma cruzi. This prevents the parasite from multiplying and spreading in the body.

Clinical trials[edit | edit source]

In Phase II clinical trials, azanidazole was found to be effective in treating Chagas disease. However, further studies are needed to confirm these results and to determine the optimal dosage and duration of treatment.

Side effects[edit | edit source]

The most common side effects of azanidazole include nausea, vomiting, abdominal pain, and headache. In rare cases, it can cause neuropathy or leukopenia.

Development[edit | edit source]

The development of azanidazole is part of a larger effort to find new treatments for neglected diseases. The DNDi is a non-profit organization that works to develop new treatments for diseases that are neglected by the pharmaceutical industry, including Chagas disease.

See also[edit | edit source]

Azanidazole Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.